Core Laboratories 10-Q 2 Nov 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Oct. 27, 2023
Cover [Abstract]
Entity Registrant Name	CORE LABORATORIES INC.
Entity Central Index Key	0001958086
Trading Symbol	CLB
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		46,723,614
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity File Number	001-41695
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6316 Windfern Road
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77040
City Area Code	713
Local Phone Number	328-2673
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock (par value $0.01)
Security Exchange Name	NYSE
Entity Tax Identification Number	98-1164194

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 16,616	$ 15,428
Accounts receivable, net of allowance for credit losses of $2,328 and $2,214 at 2023 and 2022, respectively	104,053	106,913
Inventories	75,060	60,445
Prepaid expenses	10,742	15,665
Income taxes receivable	17,401	8,190
Other current assets	4,672	5,061
TOTAL CURRENT ASSETS	228,544	211,702
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $319,040 and $314,737 at 2023 and 2022, respectively	99,499	105,028
RIGHT OF USE ASSETS	53,101	52,379
INTANGIBLES, net of accumulated amortization and impairment of $17,907 and $17,475 at 2023 and 2022, respectively	7,279	7,483
GOODWILL	99,445	99,445
DEFERRED TAX ASSETS, net	72,331	68,570
OTHER ASSETS	32,215	33,747
TOTAL ASSETS	592,414	578,354
CURRENT LIABILITIES:
Accounts payable	34,097	45,847
Accrued payroll and related costs	19,362	23,431
Taxes other than payroll and income	3,154	4,822
Unearned revenues	4,636	5,942
Operating lease liabilities	9,794	11,699
Income taxes payable	4,529	3,034
Other current liabilities	8,678	8,360
TOTAL CURRENT LIABILITIES	84,250	103,135
LONG-TERM DEBT, net	177,863	172,386
LONG-TERM OPERATING LEASE LIABILITIES	40,903	38,305
DEFERRED COMPENSATION	29,246	31,814
DEFERRED TAX LIABILITIES, net	11,882	22,877
OTHER LONG-TERM LIABILITIES	18,820	20,883
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference stock, 6,000,000 shares authorized, $0.01 par value at September 30, 2023 and EUR 0.02 par value at December 31, 2022; none issued or outstanding	0	0
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,701,102 issued and 46,698,565 outstanding at September 30, 2023; EUR 0.02 par value, 46,699,102 issued and 46,631,934 outstanding at December 31, 2022	467	1,194
Additional paid-in capital	109,103	102,254
Retained earnings	119,024	85,949
Accumulated other comprehensive income (loss)	(3,838)	(3,777)
Treasury stock (at cost), 2,537 and 67,168 shares at 2023 and 2022, respectively	(62)	(1,362)
Total Core Laboratories N.V. shareholders' equity	224,694	184,258
Non-controlling interest	4,756	4,696
TOTAL EQUITY	229,450	188,954
TOTAL LIABILITIES AND EQUITY	$ 592,414	$ 578,354

Consolidated Balance Sheets Par

Consolidated Balance Sheets Parenthetical $ in Thousands	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 € / shares
Statement of Financial Position [Abstract]
Allowance for doubtful accounts | $	$ 2,328	$ 2,214
Accumulated Depreciation | $	319,040	314,737
Accumulated amortization | $	$ 17,907	$ 17,475
Preferred stock, par value per share | (per share)	$ 0.01		€ 0.02
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share | (per share)	$ 0.01		€ 0.02
Common stock, shares authorized	200,000,000
Common stock, shares, issued	46,701,102	46,699,102
Common shares, outstanding	46,698,565	46,631,934
Treasury stock (at cost)	2,537	67,168

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
REVENUES:
Revenue	$ 125,343	$ 125,966	$ 381,580	$ 362,164
OPERATING EXPENSES:
General and administrative expense, exclusive of depreciation expense shown below	9,452	10,001	31,594	29,393
Depreciation	3,802	3,999	11,548	12,572
Amortization	127	172	362	516
Other (income) expense, net	673	(1,781)	(423)	(62)
OPERATING INCOME	14,672	14,645	40,059	25,906
Interest expense	3,147	3,138	9,812	8,489
Income before income taxes	11,525	11,507	30,247	17,417
Income tax expense (benefit)	2,305	3,856	(4,344)	4,449
Net income	9,220	7,651	34,591	12,968
Net income (loss) attributable to non-controlling interest	(37)	127	115	266
Net income attributable to Core Laboratories Inc.	$ 9,257	$ 7,524	$ 34,476	$ 12,702
EARNINGS PER SHARE INFORMATION:
Basic earnings per share	$ 0.2	$ 0.17	$ 0.74	$ 0.28
Basic earnings per share attributable to Core Laboratories Inc.	0.2	0.16	0.74	0.27
Diluted earnings per share	0.19	0.16	0.73	0.28
Diluted earnings per share attributable to Core Laboratories Inc.	$ 0.19	$ 0.16	$ 0.73	$ 0.27
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	46,692	46,338	46,667	46,319
Diluted	47,604	47,012	47,536	47,117
Service [Member]
REVENUES:
Revenue	$ 92,883	$ 87,891	$ 277,224	$ 258,036
OPERATING EXPENSES:
Cost of services and product sales exclusive of depreciation expense shown below	68,976	67,618	211,031	204,641
Product [Member]
REVENUES:
Revenue	32,460	38,075	104,356	104,128
OPERATING EXPENSES:
Cost of services and product sales exclusive of depreciation expense shown below	$ 27,641	$ 31,312	$ 87,409	$ 89,198

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 9,220	$ 7,651	$ 34,591	$ 12,968
Gain (loss) on fair value of interest rate swaps	0	0	0	6,015
Interest rate swap amount reclassified to net income (loss)	(415)	249	(187)	762
Income tax expense (benefit) on interest rate swaps reclassified to net income (loss)	87	0	39	(1,144)
Total interest rate swaps	(328)	249	(148)	5,633
Amortization of actuarial gain (loss) reclassified to net income (loss)	39	0	117	0
Income tax expense (benefit) on pension and other postretirement benefit plans reclassified to net income (loss)	(10)	0	(30)	0
Total pension and other postretirement benefit plans	29	0	87	0
Total other comprehensive income (loss)	(299)	249	(61)	5,633
Comprehensive income	8,921	7,900	34,530	18,601
Comprehensive income (loss) attributable to non-controlling interest	(37)	127	115	266
Comprehensive income attributable to Core Laboratories Inc.	$ 8,958	$ 7,773	$ 34,415	$ 18,335

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Common Shares [Member]	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Non-Controlling Interest	Common Stock Outstanding
Balance at Beginning of Period at Dec. 31, 2021	$ 161,001	$ 1,188	$ 101,120	$ 68,349	$ (10,133)	$ (4,075)	$ 4,552
Balance at Beginning of Period at Dec. 31, 2021		46,454,264				(104,867)		46,349,397
Stock-based compensation	7,452		5,209			$ 2,243
Stock-based compensation (shares)						87,330		87,330
Repurchase of common stock	(2,311)					$ (2,311)
Repurchase of common stock (shares)						(92,057)		(92,057)
Dividends paid	(1,389)			(1,389)
Non-controlling interest additions	(61)						(61)
New share issuance (shares)		0						0
Interest rate swaps, net of income taxes	5,633				5,633
Net income	12,968			12,702			266
Balance at End of Period at Sep. 30, 2022	$ 183,293	$ 1,188	106,329	79,662	(4,500)	$ (4,143)	4,757
Balance at End of Period at Sep. 30, 2022		46,454,264				(109,594)		46,344,670
Cash Dividends per Share	$ 0.03
Balance at Beginning of Period at Jun. 30, 2022	$ 173,767	$ 1,188	104,779	72,601	(4,749)	$ (4,682)	4,630
Balance at Beginning of Period at Jun. 30, 2022		46,454,264				(129,457)		46,324,807
Stock-based compensation	2,234		1,550			$ 684
Stock-based compensation (shares)						27,925		27,925
Repurchase of common stock	(145)					$ (145)
Repurchase of common stock (shares)						(8,062)		(8,062)
Dividends paid	(463)			(463)
Non-controlling interest additions	0						0
New share issuance (shares)		0						0
Interest rate swaps, net of income taxes	249				249
Net income	7,651			7,524			127
Balance at End of Period at Sep. 30, 2022	183,293	$ 1,188	106,329	79,662	(4,500)	$ (4,143)	4,757
Balance at End of Period at Sep. 30, 2022		46,454,264				(109,594)		46,344,670
Balance at Beginning of Period at Dec. 31, 2022	188,954	$ 1,194	102,254	85,949	(3,777)	$ (1,362)	4,696
Balance at Beginning of Period at Dec. 31, 2022		46,699,102				(67,168)		46,631,934
Stock-based compensation	12,406		10,688			$ 1,718
Stock-based compensation (shares)						81,672		81,672
Repurchase of common stock	(418)					$ (418)
Repurchase of common stock (shares)						(17,041)		(17,041)
Dividends paid	(1,401)			(1,401)
Non-controlling interest additions	(55)						(55)
Pension and other postretirement benefit plans, net of income taxes	87				87
Change in par value		$ (727)
Change in par value and equity related transaction costs	(4,566)		(3,839)
New share issuance (shares)		2,000						2,000
Interest rate swaps, net of income taxes	(148)				(148)
Net income	34,591			34,476			115
Balance at End of Period at Sep. 30, 2023	$ 229,450	$ 467	109,103	119,024	(3,838)	$ (62)	4,756
Balance at End of Period at Sep. 30, 2023		46,701,102				(2,537)		46,698,565
Cash Dividends per Share	$ 0.03
Balance at Beginning of Period at Jun. 30, 2023	$ 219,604	$ 467	108,030	110,234	(3,539)	$ (436)	4,848
Balance at Beginning of Period at Jun. 30, 2023		46,701,102				(20,693)		46,680,409
Stock-based compensation	2,069		1,477			$ 592
Stock-based compensation (shares)						26,127		26,127
Repurchase of common stock	(218)					$ (218)
Repurchase of common stock (shares)						(7,971)		(7,971)
Dividends paid	(467)			(467)
Non-controlling interest additions	(55)						(55)
Pension and other postretirement benefit plans, net of income taxes	29				29
New share issuance	0	$ 0	0
Change in par value		$ 0
Change in par value and equity related transaction costs	(404)		(404)
New share issuance (shares)		0						0
Interest rate swaps, net of income taxes	(328)				(328)
Net income	9,220			9,257			(37)
Balance at End of Period at Sep. 30, 2023	$ 229,450	$ 467	$ 109,103	$ 119,024	$ (3,838)	$ (62)	$ 4,756
Balance at End of Period at Sep. 30, 2023		46,701,102				(2,537)		46,698,565
Cash Dividends per Share	$ 0.01

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 34,591	$ 12,968
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Stock-based compensation	12,406	7,452
Depreciation and amortization	11,910	13,088
Changes in value of life insurance policies	(3,221)	6,407
Deferred income taxes	(14,757)	(1,807)
Other non-cash items	2,536	31
Changes in assets and liabilities:
Accounts receivable	2,872	(3,390)
Inventories	(15,707)	(9,188)
Prepaid expenses and other current assets	(3,902)	2,347
Other assets	1,711	(851)
Accounts payable	(13,101)	4,288
Accrued expenses	(3,924)	(5,165)
Unearned revenues	(1,306)	(2,005)
Other liabilities	(4,748)	(12,430)
Net cash provided by (used in) operating activities	5,360	11,745
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(7,843)	(8,195)
Patents and other intangibles	(158)	(27)
Proceeds from sale of assets	420	426
Proceeds from insurance recovery	0	583
Net proceeds on life insurance policies	3,375	2,059
Proceeds from sale of business, net of cash sold	0	240
Net cash provided by (used in) investing activities	(4,206)	(4,914)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of long-term debt	(184,000)	(49,000)
Proceeds from long-term debt	190,000	44,000
Debt issuance costs	(1,251)	(1,690)
Dividends paid	(1,401)	(1,389)
Repurchase of common stock	(418)	(2,311)
Equity related transaction costs	(2,842)	(411)
Other financing activities	(54)	(1)
Net cash provided by (used in) financing activities	34	(10,802)
NET CHANGE IN CASH AND CASH EQUIVALENTS	1,188	(3,971)
CASH AND CASH EQUIVALENTS, beginning of period	15,428	17,703
CASH AND CASH EQUIVALENTS, end of period	16,616	13,732
Supplemental disclosures of cash flow information:
Cash payments for interest	8,341	7,101
Cash payments for income taxes	16,013	10,475
Non-cash investing and financing activities:
Capital expenditures incurred but not paid for as of the end of the period	1,039	713
Equity related transaction costs incurred but not paid	$ 1,724	$ 0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 9,257	$ 7,524	$ 34,476	$ 12,702

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. DESCRIPTION OF BUSINESS References to “Core Lab”, “Core Laboratories”, the “Company”, “we”, “our” and similar phrases are used throughout this Quarterly Report on Form 10-Q (“Quarterly Report”) and relate collectively to Core Laboratories Inc. and its consolidated subsidiaries. On May 1, 2023, Core Laboratories N.V. completed its previously announced redomestication transaction (the “Redomestication Transaction”), which included (i) the merger (the “Merger”) of Core Laboratories N.V. with and into Core Laboratories Luxembourg S.A., a public limited liability company incorporated under the laws of Luxembourg, with Core Laboratories Luxembourg S.A. surviving, and (ii) following the completion of the Merger, the migration of Core Laboratories Luxembourg S.A. out of Luxembourg and its domestication as Core Laboratories Inc., a Delaware corporation. As a result of the Redomestication Transaction, all common shares in Core Laboratories N.V. were canceled and exchanged for common stock in Core Laboratories Luxembourg S.A. on a one-for-one basis. Former holders of Core Laboratories N.V. common shares now hold one share of common stock of Core Laboratories Inc. (formerly Core Laboratories Luxembourg S.A.) for each Core Laboratories N.V. common share owned immediately prior to the consummation of the Redomestication Transaction, and the business, assets, liabilities, directors and officers of Core Laboratories Inc. are now the same as the business, assets, liabilities, directors and officers of Core Laboratories N.V. immediately prior to the Redomestication Transaction. See Note 2 - Significant Accounting Policies Update – Basis of Presentation and Principles of Consolidation , Note 7 - Long-Term Debt, net , Note 8 - Pension And Other Postretirement Benefit Plans , Note 10 - Equity and Note 14 - Income Tax Expense (Benefit) for additional information regarding the Redomestication Transaction. We operate our business in two segments: (1) Reservoir Description and (2) Production Enhancement. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. For a description of the types of services and products offered by these operating segments, see Note 16 - S egment Reporting .

Significant Accounting Policies

Significant Accounting Policies Update	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Significant Accounting Policies Update	2. SIGNIFICANT ACCOUNTING POLICIES UPDATE Basis of Presentation and Principles of Consolidation The Redomestication Transaction has been accounted for as a transaction between entities under common control. Accordingly, Core Laboratories Inc. recorded the assets and liabilities transferred at their carrying amounts at the date of transfer. All common shares in Core Laboratories N.V., at par value EUR 0.02 , were canceled and exchanged for common stock in Core Laboratories Inc., at par value $ 0.01 , on a one-for-one basis. Core Laboratories Inc.'s common stock par value was decreased by $ 0.7 million for the difference between the total par value of common stock of Core Laboratories Inc. and the total par value of common shares of Core Laboratories N.V. at the date of transfer, with an offset to additional paid in capital. There is no difference between the combined separate entities prior to the Redomestication Transaction and the combined separate entities after the Redomestication Transaction, therefore, these financial statements, reported as though the exchange of equity interests had occurred at the beginning of the reporting period, and comparative information do not differ from amounts previously reported under Core Laboratories N.V.’s consolidated financial statements. These financial statements should be read in conjunction with Core Laboratories N.V.’s Quarterly Report on Form 10-Q for the three months ended March 31, 2023 and Core Laboratories N.V.’s Annual Report on Form 10-K for the year ended December 31, 2022, including Note 2 - Summary of Significant Accounting Policies. There have been no changes to the accounting policies of the combined entities during the nine months ended September 30, 2023. The accompanying unaudited interim consolidated financial statements include the accounts of Core Laboratories Inc. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Core Laboratories Inc.’s balance sheet information for the year ended December 31, 2022, was derived from the 2022 audited consolidated financial statements. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP for the annual financial statements and should be read in conjunction with the audited financial statements. Core Laboratories Inc. uses the equity method of accounting for investments in which it has less than a majority interest and does not exercise control but does exert significant influence. Non-controlling interests have been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. All inter-company transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three and nine months ended September 30, 2023, may not necessarily be indicative of the results that may be expected for the year ending December 31, 2023 . Property, Plant and Equipment We review our long-lived assets (“LLA”) for impairment when events or changes in circumstances indicate that their net book value may not be recovered over their remaining service lives. Indicators of possible impairment may include significant declines in activity levels in regions where specific assets or groups of assets are located, extended periods of idle use, declining revenue or cash flow or overall changes in general market conditions. The geopolitical conflict between Russia and Ukraine, which began in February 2022 and has continued through September 30, 2023, has resulted in disruptions to our operations in Russia and Ukraine. As of September 30, 2023, all laboratory facilities, offices, and locations in Russia and Ukraine continued to operate with no significant impact to local business operations. Therefore, we determined there was no triggering event for LLA in Russia and Ukraine, and no impairment assessments have been performed as of September 30, 2023 .

Acquisitions and Divestures

Acquisitions and Divestures	9 Months Ended
	Sep. 30, 2023
Business Combinations [Abstract]
Acquisitions and Divestures	3. ACQUISITIONS AND DIVESTURES We had no significant business acquisitions or divestures during the three and nine months ended September 30, 2023 and 2022 .

Contract Assets and Liabilities

Contract Assets and Liabilities	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Contract Assets and Liabilities	4. CONTRACT ASSETS AND LIABILITIES The balance of contract assets and liabilities consisted of the following (in thousands): September 30, December 31, Contract assets: Current $ 1,130 $ 1,148 $ 1,130 $ 1,148 Contract liabilities: Current $ 496 $ 907 Non-current 24 24 $ 520 $ 931 September 30, Estimate of when contract liabilities will be recognized as revenue: Within 12 months $ 496 Within 12 to 24 months 24 Greater than 24 months — The current portion of contract assets are included in our accounts receivable. The current portion of contract liabilities is included in unearned revenues and the non-current portion of contract liabilities is included in other long-term liabilities. We did no t recognize any impairment losses on our contract assets during the three and nine months ended September 30, 2023 and 2022 .

Inventories

Inventories	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	5. INVENTORIES Inventories consist of the following (in thousands): September 30, December 31, Finished goods $ 34,409 $ 26,534 Parts and materials 37,194 31,323 Work in progress 3,457 2,588 Total inventories $ 75,060 $ 60,445 We include freight costs incurred for shipping inventory to our clients in the cost of product sales caption in the accompanying consolidated statements of operations.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	6. LEASES We have operating leases primarily consisting of office and lab space, machinery and equipment and vehicles. The components of lease expense and other information are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Consolidated Statements of Operations: Operating lease expense $ 4,612 $ 4,061 $ 13,282 $ 12,280 Short-term lease expense 463 516 1,354 1,337 Variable lease expense 408 344 1,449 1,108 Sublease income ( 57 ) — ( 57 ) — Total lease expense $ 5,426 $ 4,921 $ 16,028 $ 14,725 Consolidated Statements of Cash Flows: Operating cash flows - operating leases payments $ 3,961 $ 3,793 $ 12,711 $ 12,799 Right of use assets obtained in exchange for 2,054 1,598 12,459 6,682 Other information: Weighted-average remaining lease term - operating leases 8.2 years 7.14 years 8.2 years 7.14 years Weighted-average discount rate - operating leases 5.29 % 4.61 % 5.29 % 4.61 % We entered into a sublease agreement that commenced on July 1, 2023, for existing office and lab space in Calgary, Alberta, Canada. The associated lease cost of the original lease exceeded the anticipated sublease income, and we recognized an impairment loss of $ 1.0 million to the related right of use asset and leasehold improvements during the nine months ended September 30, 2023. The asset write-downs are included in other income (expense), net. See Note 13 - Other (income) and expense, net . Scheduled undiscounted lease payments for non-cancellable operating leases consist of the following (in thousands): September 30, 2023 Operating Leases Operating Sublease Remainder of 2023 $ 3,560 $ ( 56 ) 2024 11,730 ( 227 ) 2025 9,375 ( 232 ) 2026 7,208 ( 237 ) 2027 5,828 ( 241 ) Thereafter 26,144 ( 163 ) Total undiscounted lease payments 63,845 ( 1,156 ) Less: Imputed interest ( 13,148 ) Total operating lease liabilities $ 50,697

Long-Term Debt, Net

Long-Term Debt, Net	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Long-Term Debt, Net	7. LONG-TERM DEBT, NET We have no finance lease obligations. Debt is summarized in the following table (in thousands): Interest Rate Maturity Date September 30, December 31, 2011 Senior Notes (1) 4.11 % September 30, 2023 $ — $ 75,000 2021 Senior Notes Series A (2) 4.09 % January 12, 2026 45,000 45,000 2021 Senior Notes Series B (2) 4.38 % January 12, 2028 15,000 15,000 2023 Senior Notes Series A (3) 7.25 % June 28, 2028 25,000 — 2023 Senior Notes Series B (3) 7.50 % June 28, 2030 25,000 — Credit Facility 71,000 40,000 Total long-term debt 181,000 175,000 Less: Debt issuance costs ( 3,137 ) ( 2,614 ) Long-term debt, net $ 177,863 $ 172,386 (1) Interest was payable semi-annually on March 30 and September 30. (2) Interest is payable semi-annually on June 30 and December 30. (3) Interest is payable semi-annually on March 28 and September 28. In connection with the Redomestication Transaction, on May 1, 2023, Core Laboratories N.V. assigned to Core Laboratories Inc., and Core Laboratories Inc. assumed all of Core Laboratories N.V.’s rights and obligations under existing agreements. We, along with our wholly owned subsidiary Core Laboratories (U.S.) Interests Holdings, Inc. (“CLIH”) as issuer, have senior notes that were issued through private placement transactions. On September 30, 2023, we retired the 2011 Senior Notes with aggregate principal amount of $ 75 million upon the maturity date. Series A and Series B of the 2021 Senior Notes were issued in 2021 (the “2021 Senior Notes”). Series A and Series B of the 2023 Senior Notes were entered on May 4, 2023, and subsequently issued and funded on June 28, 2023 (the “2023 Senior Notes”). The 2021 Senior Notes and the 2023 Senior Notes are collectively the “Senior Notes”. We, along with our wholly owned subsidiary CLIH, have a credit facility, the Eighth Amended and Restated Credit Agreement (as amended, the “Credit Facility”) for an aggregate borrowing commitment of $ 135 million with a $ 50 million “accordion” feature. The Credit Facility is secured by first priority interests in (1) substantially all of the tangible and intangible personal property, and equity interest of CLIH and certain of the Company’s U.S. and foreign subsidiary companies; and (2) instruments evidencing intercompany indebtedness owing to the Company, CLIH and certain of the Company’s U.S. and foreign subsidiary companies. Under the Credit Facility, the Secured Overnight Financing Rate (“SOFR”) plus 2.00 % to SOFR plus 3.00 % will be applied to outstanding borrowings. Any outstanding balance under the Credit Facility is due at maturity on July 25, 2026 , subject to springing maturity on July 12, 2025, if any portion of the Company’s 2021 Senior Notes Series A due January 12, 2026, in the aggregate principal amount of $ 45 million, remain outstanding on July 12, 2025, unless the Company’s liquidity equals or exceeds the principal amount of the 2021 Senior Notes Series A outstanding on such date. The available capacity at any point in time is reduced by outstanding borrowings and outstanding letters of credit which totaled approximately $ 8 million at September 30, 2023 , resulting in an available borrowing capacity under the Credit Facility of approximately $ 56 million. In addition to indebtedness under the Credit Facility, we had approximately $ 6 million of outstanding letters of credit and performance guarantees and bonds from other sources as of September 30, 2023. The terms of the Credit Facility and Senior Notes require us to meet certain covenants, including, but not limited to, an interest coverage ratio (calculated as consolidated EBITDA divided by interest expense) and a leverage ratio (calculated as consolidated net indebtedness divided by consolidated EBITDA), where consolidated EBITDA (as defined in each agreement) and interest expense are calculated using the most recent four fiscal quarters. The Credit Facility and Senior Notes include a cross-default provision, whereby a default under one agreement may trigger a default in the other agreements. The Credit Facility has more restrictive covenants with a minimum interest coverage ratio of 3.00 to 1.00 and permits a maximum leverage ratio of 2.50 to 1.00 . The Credit Facility allows non-cash charges such as impairment of assets, stock compensation and other non-cash charges to be added back in the calculation of consolidated EBITDA. The terms of our Credit Facility also allow us to negotiate in good faith to amend any ratio or requirement to preserve the original intent of the agreement if any change in accounting principles would affect the computation of any financial ratio or covenant of the Credit Facility. In accordance with the terms of the Credit Facility, our leverage ratio is 1.92 , and our interest coverage ratio is 6.63 , each for the period ended September 30, 2023. We believe that we are in compliance with all covenants contained in our Credit Facility and Senior Notes. Certain of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes. The estimated fair value of total debt at September 30, 2023, and December 31, 2022 , approximated the book value of total debt. The fair value was estimated using Level 2 inputs by calculating the sum of the discounted future interest and principal payments through the maturity date.

Pension and Other Postretiremen

Pension and Other Postretirement Benefit Plans	9 Months Ended
	Sep. 30, 2023
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefit Plans	8. PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS Prior to January 2020, one of our subsidiaries provided a noncontributory defined benefit pension plan covering substantially all of our Dutch employees (“Dutch Plan”) who were hired prior to 2000. This pension benefit was based on years of service and final pay or career average pay, depending on when the employee began participating. The Dutch Plan was curtailed prior to January 2020, and these employees have been moved into the Dutch defined contribution plan. However, the unconditional indexation for this group of participants continues for so long as they remain in active service with the Company. The following table summarizes the components of net periodic pension cost under the Dutch Plan (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Interest cost $ 374 $ 140 $ 1,113 $ 443 Expected return on plan assets ( 336 ) ( 132 ) ( 992 ) ( 416 ) Net periodic pension cost $ 38 $ 8 $ 121 $ 27 During the nine months ended September 30, 2023, we made additional contributions to the Dutch Plan of approximately $ 1.8 million for the indexation. In connection with the Redomestication Transaction, Core Laboratories N.V. assigned to Core Laboratories Inc., and Core Laboratories Inc. assumed, all of Core Laboratories N.V.’s rights and obligations under compensation or benefit plans, policies and arrangements previously maintained by Core Laboratories N.V., including the Supplemental Executive Retirement Plan, Deferred Compensation Plan, Employment Agreements and Profit Sharing and Retirement Plan.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCIES We have been and may, from time to time, be named as a defendant in legal actions that arise in the ordinary course of business. These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our services and products. A liability is accrued when a loss is both probable and can be reasonably estimated. See Note 7 - Long-term Debt, net for amounts committed under letters of credits and performance guarantees and bonds.

Equity

Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Equity	10. EQUITY Common Stock In connection with the Redomestication Transaction, all common shares in Core Laboratories N.V. at par value EUR 0.02 , were canceled and exchanged for common stock in Core Laboratories Inc. at par value $ 0.01 , on a one-for-one basis. Core Laboratories Inc.’s common stock par value was decreased by $ 0.7 million for the difference between the total par value of common stock of Core Laboratories Inc. and the total par value of common shares of Core Laboratories N.V. at the date of transfer, with an offset to additional paid in capital. Equity related transaction costs associated with the Redomestication Transaction of $ 4.6 million have been charged to additional paid in capital. In addition, Core Laboratories N.V. assigned to Core Laboratories Inc., and Core Laboratories Inc. assumed, all of Core Laboratories N.V.’s rights and obligations under the 2014 Non-Employee Director Stock Incentive Plan and the 2020 Long Term Incentive Plan. Each outstanding Core Laboratories N.V. incentive award thereunder became a Core Laboratories Inc. incentive award that is subject to substantially the same terms and conditions as the former Core Laboratories N.V. incentive award, except, in the case of equity-based Core Laboratories N.V. incentive awards, the security issuable upon exercise or settlement of the incentive award, as applicable, will be a share of Core Laboratories Inc. common stock rather than a Core Laboratories N.V. common share. During the nine months ended September 30, 2023 , we distributed 2,000 shares of common stock upon vesting of stock-based awards. On June 9, 2022, we entered into an Equity Distribution Agreement with certain banks for the issuance and sale of up to $ 60.0 million of our common stock allowing sales of our common stock to be made by any method deemed to be an “at-the-market offering” (“ATM Program”) as defined in Rule 415 under the Securities Act of 1933. On July 17, 2023, the Company terminated the Equity Distribution Agreement. As a result of the termination of the Equity Distribution Agreement, the Company suspended and terminated the 2022 ATM Program and therefore will not offer or sell any shares under the 2022 ATM Program. The Company did not sell any shares under the Equity Distribution Agreement. Treasury Stock During the three and nine months ended September 30, 2023 , we distributed 26,127 and 81,672 shares of treasury stock, respectively, upon vesting of stock-based awards. During the three and nine months ended September 30, 2023 , we repurchased 7,971 and 17,041 shares of our common stock, respectively, for $ 218 thousand and $ 418 thousand, respectively, which were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participants' tax burdens resulting from the issuance of common stock under that plan. Such shares of common stock, unless canceled, may be reissued for a variety of purposes such as future acquisitions, non-employee director stock awards or employee stock awards. Dividend Policy In March, May and August 2023, we paid quarterly cash dividends of $ 0.01 per share of common stock. In addition, on November 1, 2023 , we declared a quarterly dividend of $ 0.01 per share of common stock for shareholders of record on November 13, 2023, and payable on December 4, 2023. Accumulated Other Comprehensive Income (Loss) Amounts recognized, net of income tax, in accumulated other comprehensive income (loss) consist of the following (in thousands): September 30, December 31, Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss $ ( 5,019 ) $ ( 5,108 ) Interest rate swaps - net gain (loss) on fair value 1,181 1,331 Total accumulated other comprehensive income (loss) $ ( 3,838 ) $ ( 3,777 )

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	11. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We are exposed to market risks related to fluctuations in interest rates. To mitigate these risks, we may utilize derivative instruments in the form of interest rate swaps. We do not enter into derivative transactions for speculative purposes. Under the Company’s Credit Facility, the SOFR plus 2.00 % to SOFR plus 3.00 % will be applied to outstanding borrowings. See Note 7 - Long-Term Debt, net for additional information. The Company has elected to apply the optional expedient for hedging relationships affected by reference rate reform. Accordingly, no outstanding balance on the Credit Facility with a SOFR rate will preclude cash flow hedging with existing London Inter-Bank Offer Rate (“LIBOR”) hedging instruments. In August 2014, we entered into a swap agreement with a notional amount of $ 25 million (“2014 Variable-to-Fixed Swap”), and the LIBOR portion of the interest rate was fixed at 2.5 % through August 29, 2024 . In February 2020, we entered into a second swap agreement with a notional amount of $ 25 million (“2020 Variable-to-Fixed Swap”), and the LIBOR portion of the interest rate was fixed at 1.3 % through February 28, 2025 . These interest rate swap agreements were terminated, dedesignated and settled in March 2021. The hedging relationship is highly effective; therefore, gains and losses on these swaps will be reclassified into interest expense in accordance with the forecasted transactions or the scheduled interest payments on the Credit Facility. The outstanding balance on our Credit Facility was reduced to zero at June 30, 2023, and approximately $ 0.2 million of losses were reclassified to interest expense associated with the ineffective period of the hedging relationship from the end of June to the end of September 2023, as it became probable that certain of the forecasted transactions would not occur within the originally specified time period. Remaining losses on these swaps included in accumulated other comprehensive income (loss) as of September 30, 2023, are $ 0.5 million substantially all of which is expected to be reclassified into earnings within the next 12 months as interest payments are made on the Company’s Credit Facility. In March 2021, we entered into a new forward interest rate swap agreement and carried the fair value of the terminated 2014 and 2020 Variable-to-Fixed Swaps into the new agreement in a “blend and extend” structured transaction. The purpose of this forward interest rate swap agreement is to fix the underlying risk-free rate, that would be associated with the anticipated issuance of new long-term debt by the Company in future periods. The forward interest rate swap would hedge the risk-free rate on forecasted long-term debt for a maximum of 11 years through March 2033. Risk associated with future changes in the 10-year LIBOR interest rates have been fixed up to a notional amount of $ 60 million with this instrument. The interest rate swap qualifies as a cash flow hedging instrument. This forward interest rate swap agreement was terminated and settled in April 2022. The hedging relationship is highly effective, therefore, the gain on the termination of the forward interest rate swap was included in accumulated other comprehensive income (loss). On June 28, 2023, the Company issued the 2023 Senior Notes in the aggregate principal amount of $ 50 million at fixed interest rates of 7.25 % and 7.50 %. The Company has elected to apply the optional expedient for hedging relationships affected by reference rate reform. Accordingly, no outstanding balance on the 2023 Senior Notes will preclude cash flow hedging with the existing LIBOR hedging instrument. The Company recognized a gain of $ 0.4 million in earnings for the $ 10 million over hedged portion of the interest rate swap. The remaining gain on this swap included in accumulated other comprehensive income (loss) at September 30, 2023, is $ 1.7 million of which $ 1.3 million will be reclassified into earnings within the next 12 months as interest expense in accordance with the forecasted transactions or the scheduled interest payments on the 2023 Senior Notes. As of September 30, 2023, the aggregated gains and losses on these interest swaps that is included in accumulated other comprehensive income (loss) are a net gain of $ 1.2 million. At September 30, 2023 , we had fixed rate long-term debt aggregating $ 110 million and $ 71 million variable rate long-term debt. The effect of the interest rate swaps on the consolidated statements of operations is as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Income Statement Derivatives designated as hedges: 5 year interest rate swap $ — $ 84 $ 211 $ 264 Increase (decrease) to interest expense 10 year interest rate swap ( 415 ) 165 ( 398 ) 498 Increase (decrease) to interest expense $ ( 415 ) $ 249 $ ( 187 ) $ 762

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Financial Instruments	12. FINANCIAL INSTRUMENTS The Company’s only financial assets and liabilities which are measured at fair value on a recurring basis relate to certain aspects of the Company’s benefit plans. We use the market approach to determine the fair value of these assets and liabilities using significant other observable inputs (Level 2) with the assistance of third-party specialists. We do not have any assets or liabilities measured at fair value on a recurring basis using quoted prices in an active market (Level 1) or significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the financial assets and liabilities are recorded in general and administrative expense in the consolidated statements of operations. The following table summarizes the fair value balances (in thousands): Fair Value Measurement at September 30, 2023 Total Level 1 Level 2 Level 3 Assets: Company owned life insurance policies (1) $ 23,635 $ — $ 23,635 $ — $ 23,635 $ — $ 23,635 $ — Liabilities: Deferred compensation liabilities $ 16,912 $ — $ 16,912 $ — $ 16,912 $ — $ 16,912 $ — Fair Value Measurement at December 31, 2022 Total Level 1 Level 2 Level 3 Assets: Company owned life insurance policies (1) $ 23,787 $ — $ 23,787 $ — $ 23,787 $ — $ 23,787 $ — Liabilities: Deferred compensation liabilities $ 16,284 $ — $ 16,284 $ — $ 16,284 $ — $ 16,284 $ — (1) Company owned life insurance policies have cash surrender value and are intended to assist in funding deferred compensation liabilities and other benefit plans.

Other (Income) Expense, Net

Other (Income) Expense, Net	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Other (Income) Expense, Net	13. OTHER (INCOME) EXPENSE, NET The components of other (income) expense, net, are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 (Gain) loss on sale of assets $ ( 76 ) $ ( 96 ) $ ( 109 ) $ ( 363 ) Results of non-consolidated subsidiaries ( 135 ) ( 59 ) ( 334 ) ( 173 ) Foreign exchange (gain) loss, net 238 ( 1,303 ) ( 292 ) ( 462 ) Rents and royalties ( 205 ) ( 222 ) ( 460 ) ( 533 ) Return on pension assets and other pension costs ( 336 ) ( 132 ) ( 992 ) ( 416 ) Loss on lease abandonment and other exit costs 505 — 1,146 — Assets write-down 128 — 1,143 — Severance and other charges — — — 3,332 Insurance and other settlements — — ( 604 ) ( 669 ) ATM termination costs 455 — 455 — Other, net 99 31 ( 376 ) ( 778 ) Total other (income) expense, net $ 673 $ ( 1,781 ) $ ( 423 ) $ ( 62 ) During the three and nine months ended September 30, 2023 , we abandoned certain leases in the U.S. and Canada and incurred costs of $ 0.5 million and $ 1.1 million, respectively. We integrated and relocated these facilities and wrote down related leasehold improvements and right of use assets of $ 0.1 million and $ 1.1 million, respectively. During the nine months ended September 30, 2023 , the State of Louisiana expropriated the access road to one of our facilities and paid us a settlement of $ 0.6 million. During the nine months ended September 30, 2022 , we received insurance settlements of $ 0.7 million associated with business interruptions and property losses to certain facilities caused by the North America mid-continent winter storm in February 2021. During the three and nine months ended September 30, 2023 , we wrote off previously deferred costs of $ 0.5 million upon termination of our ATM Program. See Note 10 - Equity for additional information. Foreign exchange (gain) loss, net by currency is summarized in the following table (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 British Pound $ ( 30 ) $ ( 187 ) $ ( 211 ) $ ( 195 ) Canadian Dollar 98 130 92 159 Colombian Peso ( 12 ) ( 309 ) 120 ( 398 ) Euro 13 ( 501 ) ( 4 ) ( 956 ) Russian Ruble 15 ( 533 ) ( 326 ) 572 Turkish Lira ( 24 ) ( 7 ) ( 472 ) 117 Other currencies, net 178 104 509 239 Foreign exchange (gain) loss, net $ 238 $ ( 1,303 ) $ ( 292 ) $ ( 462 )

Income Tax Expense (Benefit)

Income Tax Expense (Benefit)	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	14. INCOME TAX EXPENSE (BENEFIT) The Company recorded income tax expense of $ 2.3 million and an income tax benefit of $ 4.3 million for the three and nine months ended September 30, 2023, respectively, compared to an income tax expense of $ 3.9 million and $ 4.4 million for the three and nine months ended September 30, 2022, respectively. The effective tax rate for the three and nine months ended September 30, 2023, was 20 % and ( 14.4 %), respectively. The effective tax rate for the three and nine months ended September 30, 2022, was 33.5 % and 25.5 %, respectively. The tax rate for the three months ended September 30, 2023, was largely impacted by the earnings mix of jurisdictions subject to tax for that period and items discrete to that period. The tax rate for the nine months ended September 30, 2023, was largely impacted by the reversal of net deferred tax liabilities attributable to Core Laboratories N.V. which will not be realized subsequent to the Redomestication Transaction on May 1, 2023. The tax rate for the three months ended September 30, 2022, was largely impacted by nondeductible items and the earnings mix of jurisdictions subject to tax for that period. The tax rate for the nine months ended September 30, 2022, was largely impacted by taxable gains in local jurisdictions associated with foreign currency translation of U.S. dollar denominated receivables, primarily in the United Kingdom and Turkey. The increased tax was partially offset by the release of withholding tax of $ 0.6 million related to unrepatriated earnings of our Russian subsidiary amounting to $ 12.0 million, which are not expected to be distributed in the foreseeable future.

Earnings per Share

Earnings per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings per Share	15. EARNINGS PER SHARE We compute basic earnings per share by dividing net income attributable to Core Laboratories Inc. by the number of weighted average common shares outstanding during the period. Diluted earnings per share includes the incremental effect of contingently issuable shares from performance and restricted stock awards, as determined using the treasury stock method. The Redomestication Transaction had no effect on earnings per share for the periods presented. The following table summarizes the calculation of weighted average common shares outstanding used in the computation of basic and diluted earnings per share (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Weighted average common shares outstanding - basic 46,692 46,338 46,667 46,319 Effect of dilutive securities: Restricted shares 106 62 96 107 Performance shares 806 612 773 691 Weighted average common shares outstanding - diluted 47,604 47,012 47,536 47,117

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Reporting	16. SEGMENT REPORTING We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. • Reservoir Description: Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients' reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services relating to these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, hydrogen storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage. • Production Enhancement: Includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. We provide integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects. We use the same accounting policies to prepare our operating segment results as are used to prepare our consolidated financial statements. All interest and other non-operating income (expense) is attributable to Corporate & Other and is not allocated to specific operating segments. Summarized financial information concerning our operating segments is shown in the following table (in thousands): Reservoir Production Corporate & (1) Consolidated Three months ended September 30, 2023 Revenue from unaffiliated clients $ 85,145 $ 40,198 $ — $ 125,343 Inter-segment revenue 16 25 ( 41 ) — Segment operating income (loss) 12,992 1,544 136 14,672 Total assets (at end of period) 302,769 163,395 126,250 592,414 Capital expenditures 2,840 237 384 3,461 Depreciation and amortization 2,712 1,049 168 3,929 Three months ended September 30, 2022 Revenue from unaffiliated clients $ 78,996 $ 46,970 $ — $ 125,966 Inter-segment revenue 103 89 ( 192 ) — Segment operating income (loss) 9,798 4,417 430 14,645 Total assets (at end of period) 303,102 150,005 117,083 570,190 Capital expenditures 1,590 1,096 16 2,702 Depreciation and amortization 2,872 1,075 224 4,171 Nine months ended September 30, 2023 Revenue from unaffiliated clients $ 248,717 $ 132,863 $ — $ 381,580 Inter-segment revenue 145 144 ( 289 ) — Segment operating income (loss) 28,780 10,324 955 40,059 Total assets (at end of period) 302,769 163,395 126,250 592,414 Capital expenditures 5,879 1,237 727 7,843 Depreciation and amortization 8,374 3,034 502 11,910 Nine months ended September 30, 2022 Revenue from unaffiliated clients $ 229,567 $ 132,597 $ — $ 362,164 Inter-segment revenue 424 183 ( 607 ) — Segment operating income (loss) 16,085 8,447 1,374 25,906 Total assets (at end of period) 303,102 150,005 117,083 570,190 Capital expenditures 5,721 1,984 490 8,195 Depreciation and amortization 8,804 3,581 703 13,088 (1) "Corporate & Other" represents those items that are not directly related to a particular operating segment and eliminations.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Redomestication Transaction has been accounted for as a transaction between entities under common control. Accordingly, Core Laboratories Inc. recorded the assets and liabilities transferred at their carrying amounts at the date of transfer. All common shares in Core Laboratories N.V., at par value EUR 0.02 , were canceled and exchanged for common stock in Core Laboratories Inc., at par value $ 0.01 , on a one-for-one basis. Core Laboratories Inc.'s common stock par value was decreased by $ 0.7 million for the difference between the total par value of common stock of Core Laboratories Inc. and the total par value of common shares of Core Laboratories N.V. at the date of transfer, with an offset to additional paid in capital. There is no difference between the combined separate entities prior to the Redomestication Transaction and the combined separate entities after the Redomestication Transaction, therefore, these financial statements, reported as though the exchange of equity interests had occurred at the beginning of the reporting period, and comparative information do not differ from amounts previously reported under Core Laboratories N.V.’s consolidated financial statements. These financial statements should be read in conjunction with Core Laboratories N.V.’s Quarterly Report on Form 10-Q for the three months ended March 31, 2023 and Core Laboratories N.V.’s Annual Report on Form 10-K for the year ended December 31, 2022, including Note 2 - Summary of Significant Accounting Policies. There have been no changes to the accounting policies of the combined entities during the nine months ended September 30, 2023. The accompanying unaudited interim consolidated financial statements include the accounts of Core Laboratories Inc. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Core Laboratories Inc.’s balance sheet information for the year ended December 31, 2022, was derived from the 2022 audited consolidated financial statements. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP for the annual financial statements and should be read in conjunction with the audited financial statements. Core Laboratories Inc. uses the equity method of accounting for investments in which it has less than a majority interest and does not exercise control but does exert significant influence. Non-controlling interests have been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. All inter-company transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three and nine months ended September 30, 2023, may not necessarily be indicative of the results that may be expected for the year ending December 31, 2023 .
Property, Plant and Equipment	Property, Plant and Equipment We review our long-lived assets (“LLA”) for impairment when events or changes in circumstances indicate that their net book value may not be recovered over their remaining service lives. Indicators of possible impairment may include significant declines in activity levels in regions where specific assets or groups of assets are located, extended periods of idle use, declining revenue or cash flow or overall changes in general market conditions. The geopolitical conflict between Russia and Ukraine, which began in February 2022 and has continued through September 30, 2023, has resulted in disruptions to our operations in Russia and Ukraine. As of September 30, 2023, all laboratory facilities, offices, and locations in Russia and Ukraine continued to operate with no significant impact to local business operations. Therefore, we determined there was no triggering event for LLA in Russia and Ukraine, and no impairment assessments have been performed as of September 30, 2023 .

Contract Assets and Liabiliti_2

Contract Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Contract Assets and Liabilities	The balance of contract assets and liabilities consisted of the following (in thousands): September 30, December 31, Contract assets: Current $ 1,130 $ 1,148 $ 1,130 $ 1,148 Contract liabilities: Current $ 496 $ 907 Non-current 24 24 $ 520 $ 931 September 30, Estimate of when contract liabilities will be recognized as revenue: Within 12 months $ 496 Within 12 to 24 months 24 Greater than 24 months —

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): September 30, December 31, Finished goods $ 34,409 $ 26,534 Parts and materials 37,194 31,323 Work in progress 3,457 2,588 Total inventories $ 75,060 $ 60,445

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Components of Lease Expense and Other Information	The components of lease expense and other information are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Consolidated Statements of Operations: Operating lease expense $ 4,612 $ 4,061 $ 13,282 $ 12,280 Short-term lease expense 463 516 1,354 1,337 Variable lease expense 408 344 1,449 1,108 Sublease income ( 57 ) — ( 57 ) — Total lease expense $ 5,426 $ 4,921 $ 16,028 $ 14,725 Consolidated Statements of Cash Flows: Operating cash flows - operating leases payments $ 3,961 $ 3,793 $ 12,711 $ 12,799 Right of use assets obtained in exchange for 2,054 1,598 12,459 6,682 Other information: Weighted-average remaining lease term - operating leases 8.2 years 7.14 years 8.2 years 7.14 years Weighted-average discount rate - operating leases 5.29 % 4.61 % 5.29 % 4.61 %
Schedule of Undiscounted Cash Flows for Non-cancellable Leases	Scheduled undiscounted lease payments for non-cancellable operating leases consist of the following (in thousands): September 30, 2023 Operating Leases Operating Sublease Remainder of 2023 $ 3,560 $ ( 56 ) 2024 11,730 ( 227 ) 2025 9,375 ( 232 ) 2026 7,208 ( 237 ) 2027 5,828 ( 241 ) Thereafter 26,144 ( 163 ) Total undiscounted lease payments 63,845 ( 1,156 ) Less: Imputed interest ( 13,148 ) Total operating lease liabilities $ 50,697

Long-Term Debt, Net (Tables)

Long-Term Debt, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt is summarized in the following table (in thousands): Interest Rate Maturity Date September 30, December 31, 2011 Senior Notes (1) 4.11 % September 30, 2023 $ — $ 75,000 2021 Senior Notes Series A (2) 4.09 % January 12, 2026 45,000 45,000 2021 Senior Notes Series B (2) 4.38 % January 12, 2028 15,000 15,000 2023 Senior Notes Series A (3) 7.25 % June 28, 2028 25,000 — 2023 Senior Notes Series B (3) 7.50 % June 28, 2030 25,000 — Credit Facility 71,000 40,000 Total long-term debt 181,000 175,000 Less: Debt issuance costs ( 3,137 ) ( 2,614 ) Long-term debt, net $ 177,863 $ 172,386 (1) Interest was payable semi-annually on March 30 and September 30. (2) Interest is payable semi-annually on June 30 and December 30. (3) Interest is payable semi-annually on March 28 and September 28.

Pension and Other Postretirem_2

Pension and Other Postretirement Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2023
Retirement Benefits [Abstract]
Schedule of Components of Net Periodic Pension Cost	The following table summarizes the components of net periodic pension cost under the Dutch Plan (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Interest cost $ 374 $ 140 $ 1,113 $ 443 Expected return on plan assets ( 336 ) ( 132 ) ( 992 ) ( 416 ) Net periodic pension cost $ 38 $ 8 $ 121 $ 27

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Amounts recognized, net of income tax, in accumulated other comprehensive income (loss) consist of the following (in thousands): September 30, December 31, Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss $ ( 5,019 ) $ ( 5,108 ) Interest rate swaps - net gain (loss) on fair value 1,181 1,331 Total accumulated other comprehensive income (loss) $ ( 3,838 ) $ ( 3,777 )

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)	The effect of the interest rate swaps on the consolidated statements of operations is as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Income Statement Derivatives designated as hedges: 5 year interest rate swap $ — $ 84 $ 211 $ 264 Increase (decrease) to interest expense 10 year interest rate swap ( 415 ) 165 ( 398 ) 498 Increase (decrease) to interest expense $ ( 415 ) $ 249 $ ( 187 ) $ 762

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Fair Value Balances	The following table summarizes the fair value balances (in thousands): Fair Value Measurement at September 30, 2023 Total Level 1 Level 2 Level 3 Assets: Company owned life insurance policies (1) $ 23,635 $ — $ 23,635 $ — $ 23,635 $ — $ 23,635 $ — Liabilities: Deferred compensation liabilities $ 16,912 $ — $ 16,912 $ — $ 16,912 $ — $ 16,912 $ — Fair Value Measurement at December 31, 2022 Total Level 1 Level 2 Level 3 Assets: Company owned life insurance policies (1) $ 23,787 $ — $ 23,787 $ — $ 23,787 $ — $ 23,787 $ — Liabilities: Deferred compensation liabilities $ 16,284 $ — $ 16,284 $ — $ 16,284 $ — $ 16,284 $ — (1) Company owned life insurance policies have cash surrender value and are intended to assist in funding deferred compensation liabilities and other benefit plans.

Other (Income) Expense, Net (Ta

Other (Income) Expense, Net (Tables)	9 Months Ended
	Sep. 30, 2023
Other Income and Expenses [Abstract]
Schedule of Other Operating Cost and Expense, by Component	The components of other (income) expense, net, are as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 (Gain) loss on sale of assets $ ( 76 ) $ ( 96 ) $ ( 109 ) $ ( 363 ) Results of non-consolidated subsidiaries ( 135 ) ( 59 ) ( 334 ) ( 173 ) Foreign exchange (gain) loss, net 238 ( 1,303 ) ( 292 ) ( 462 ) Rents and royalties ( 205 ) ( 222 ) ( 460 ) ( 533 ) Return on pension assets and other pension costs ( 336 ) ( 132 ) ( 992 ) ( 416 ) Loss on lease abandonment and other exit costs 505 — 1,146 — Assets write-down 128 — 1,143 — Severance and other charges — — — 3,332 Insurance and other settlements — — ( 604 ) ( 669 ) ATM termination costs 455 — 455 — Other, net 99 31 ( 376 ) ( 778 ) Total other (income) expense, net $ 673 $ ( 1,781 ) $ ( 423 ) $ ( 62 )
Foreign Currency (Gain) Loss, Net By Currency	Foreign exchange (gain) loss, net by currency is summarized in the following table (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 British Pound $ ( 30 ) $ ( 187 ) $ ( 211 ) $ ( 195 ) Canadian Dollar 98 130 92 159 Colombian Peso ( 12 ) ( 309 ) 120 ( 398 ) Euro 13 ( 501 ) ( 4 ) ( 956 ) Russian Ruble 15 ( 533 ) ( 326 ) 572 Turkish Lira ( 24 ) ( 7 ) ( 472 ) 117 Other currencies, net 178 104 509 239 Foreign exchange (gain) loss, net $ 238 $ ( 1,303 ) $ ( 292 ) $ ( 462 )

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares	The following table summarizes the calculation of weighted average common shares outstanding used in the computation of basic and diluted earnings per share (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Weighted average common shares outstanding - basic 46,692 46,338 46,667 46,319 Effect of dilutive securities: Restricted shares 106 62 96 107 Performance shares 806 612 773 691 Weighted average common shares outstanding - diluted 47,604 47,012 47,536 47,117

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Summarized financial information concerning our operating segments is shown in the following table (in thousands): Reservoir Production Corporate & (1) Consolidated Three months ended September 30, 2023 Revenue from unaffiliated clients $ 85,145 $ 40,198 $ — $ 125,343 Inter-segment revenue 16 25 ( 41 ) — Segment operating income (loss) 12,992 1,544 136 14,672 Total assets (at end of period) 302,769 163,395 126,250 592,414 Capital expenditures 2,840 237 384 3,461 Depreciation and amortization 2,712 1,049 168 3,929 Three months ended September 30, 2022 Revenue from unaffiliated clients $ 78,996 $ 46,970 $ — $ 125,966 Inter-segment revenue 103 89 ( 192 ) — Segment operating income (loss) 9,798 4,417 430 14,645 Total assets (at end of period) 303,102 150,005 117,083 570,190 Capital expenditures 1,590 1,096 16 2,702 Depreciation and amortization 2,872 1,075 224 4,171 Nine months ended September 30, 2023 Revenue from unaffiliated clients $ 248,717 $ 132,863 $ — $ 381,580 Inter-segment revenue 145 144 ( 289 ) — Segment operating income (loss) 28,780 10,324 955 40,059 Total assets (at end of period) 302,769 163,395 126,250 592,414 Capital expenditures 5,879 1,237 727 7,843 Depreciation and amortization 8,374 3,034 502 11,910 Nine months ended September 30, 2022 Revenue from unaffiliated clients $ 229,567 $ 132,597 $ — $ 362,164 Inter-segment revenue 424 183 ( 607 ) — Segment operating income (loss) 16,085 8,447 1,374 25,906 Total assets (at end of period) 303,102 150,005 117,083 570,190 Capital expenditures 5,721 1,984 490 8,195 Depreciation and amortization 8,804 3,581 703 13,088

Description of Business (Detail

Description of Business (Details)	9 Months Ended
	Sep. 30, 2023 Segment
Basis Of Presentation [Line Items]
Number of operating segments	2

Significant Accounting Polici_3

Significant Accounting Policies Update - Additional Information (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2023 € / shares	Dec. 31, 2022 € / shares
Significant Accounting Policies [Line Items]
Common stock, par value per share | (per share)	$ 0.01		€ 0.02
Core Laboratories Inc.
Significant Accounting Policies [Line Items]
Amount decreased due to difference between the total par value of common shares	$ 0.7
Common stock, par value per share | (per share)	$ 0.01	€ 0.02

Acquisitions and Divestures - A

Acquisitions and Divestures - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Business Combinations [Abstract]
Goodwill, acquired during period	$ 0	$ 0	$ 0	$ 0

Contract Assets and Liabiliti_3

Contract Assets and Liabilities - Contract Assets and Liabilities Changes in Net Contract Assets (Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Contract assets
Current	$ 1,130	$ 1,148
Contract asset	1,130	1,148
Contract Liabilities
Current	496	907
Non-current	24	24
Contract liabilities	$ 520	$ 931

Contract Assets and Liabiliti_4

Contract Assets and Liabilities - Contract Assets and Liabilities Current and Long-term Contract Liabilities (Details 1) $ in Thousands	Sep. 30, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liability	$ 496
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liability	$ 24
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liability	$ 0
Revenue, remaining performance obligation, expected timing of satisfaction, period	24 months

Contract Assets and Liabiliti_5

Contract Assets and Liabilities - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Impairment losses on contract assets	$ 0	$ 0	$ 0	$ 0

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 34,409	$ 26,534
Parts and materials	37,194	31,323
Work in progress	3,457	2,588
Total inventories	$ 75,060	$ 60,445

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease expense	$ 4,612	$ 4,061	$ 13,282	$ 12,280
Short-term lease expense	463	516	1,354	1,337
Variable lease expense	408	344	1,449	1,108
Sublease income	(57)	0	(57)	0
Total lease expense	5,426	4,921	16,028	14,725
Operating cash flows - operating leases payments	3,961	3,793	12,711	12,799
Right of use assets obtained (released) in exchange for operating lease obligations	$ 2,054	$ 1,598	$ 12,459	$ 6,682
Weighted-average remaining lease term - operating leases	8 years 2 months 12 days	7 years 1 month 20 days	8 years 2 months 12 days	7 years 1 month 20 days
Weighted-average discount rate - operating leases	5.29%	4.61%	5.29%	4.61%

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Cash Flows for Non-cancellable Leases (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating Leased Assets [Line Items]
Remainder of 2023	$ 3,560
2024	11,730
2025	9,375
2026	7,208
2027	5,828
Thereafter	26,144
Total undiscounted lease payments	63,845
Less: Imputed interest	(13,148)
Total operating lease liabilities	50,697
Remainder of 2023	(56)
2024	(227)
2025	(232)
2026	(237)
2027	(241)
Thereafter	(163)
Total operating lease liabilities	$ (1,156)

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Leases [Abstract]
Impairment loss on lease	$ 1

Long-Term Debt, Net - Additiona

Long-Term Debt, Net - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
Financing lease obligations	$ 0
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Financing lease obligations
Face amount	$ 75,000
Maturity date	Jul. 25, 2026
Line of credit facility reduced minimum borrowing capacity	$ 50,000
Performance bonds under credit facility	8,000
Remaining borrowing capacity	56,000
Performance bonds	$ 6,000
Maximum [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	3%
Minimum [Member]
Debt Instrument [Line Items]
Current borrowing capacity	$ 135,000
Basis spread on variable rate	2%
2021 Senior Notes Series A [Member]
Debt Instrument [Line Items]
Face amount	$ 45,000
Line of Credit [Member]
Debt Instrument [Line Items]
Interest coverage ratio, minimum	3%
Calculated covenant leverage ratio	1.92%
Calculated interest coverage ratio	6.63%
Line of Credit [Member] | Maximum [Member]
Debt Instrument [Line Items]
Maximum leverage ratio permitted	2.5
Line of Credit [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum leverage ratio permitted	1

Long-Term Debt, Net - Schedule

Long-Term Debt, Net - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Maturity date		Jul. 25, 2026
Total long-term debt		$ 181,000		$ 175,000
Less: Debt issuance costs		(3,137)		(2,614)
Long-term debt, net		$ 177,863		172,386
2011 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, interest rate	[1]	4.11%
Maturity date	[1]	Sep. 30, 2023
Total long-term debt	[1]	$ 0		75,000
Credit Facility [Member]
Debt Instrument [Line Items]
Total long-term debt		$ 71,000	$ 0	40,000
Series A [Member] | 2021 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, interest rate	[2]	4.09%
Maturity date	[2]	Jan. 12, 2026
Total long-term debt	[2]	$ 45,000		45,000
Series A [Member] | 2023 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, interest rate	[3]	7.25%
Maturity date	[3]	Jun. 28, 2028
Total long-term debt	[3]	$ 25,000		0
Series B [Member] | 2021 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, interest rate	[2]	4.38%
Maturity date	[2]	Jan. 12, 2028
Total long-term debt	[2]	$ 15,000		15,000
Series B [Member] | 2023 Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, interest rate	[3]	7.50%
Maturity date	[3]	Jun. 28, 2030
Total long-term debt	[3]	$ 25,000		$ 0
[1] (1) Interest was payable semi-annually on March 30 and September 30. (2) Interest is payable semi-annually on June 30 and December 30. (3) Interest is payable semi-annually on March 28 and September 28.

Pension and Other Postretirem_3

Pension and Other Postretirement Benefit Plans - Schedule of Components of Net Periodic Pension Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Retirement Benefits [Abstract]
Interest cost	$ 374	$ 140	$ 1,113	$ 443
Expected return on plan assets	(336)	(132)	(992)	(416)
Net periodic pension cost	$ 38	$ 8	$ 121	$ 27

Pension and Other Postretirem_4

Pension and Other Postretirement Benefit Plans - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Retirement Benefits [Abstract]
Contributions by employer	$ 1.8

Equity - Additional Information

Equity - Additional Information (Details) $ / shares in Units, $ in Thousands			1 Months Ended			3 Months Ended			9 Months Ended
	Nov. 01, 2023 $ / shares	Jun. 09, 2022 USD ($)	Aug. 31, 2023 $ / shares	May 31, 2023 $ / shares	Mar. 31, 2023 $ / shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Jun. 30, 2022 $ / shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2023 € / shares shares	Dec. 31, 2022 € / shares shares
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, par value per share | (per share)						$ 0.01			$ 0.01			€ 0.02
Common stock, shares, issued | shares						46,701,102			46,701,102		46,701,102	46,699,102
Repurchase of common shares (shares) | shares						7,971			17,041
Treasury stock, value						$ 218	$ 145		$ 418	$ 2,311
Treasury stock, value						$ 218			$ 418
Treasury stock reissued | shares						26,127			81,672
Cash dividends per share | $ / shares			$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01	$ 0.03	$ 0.03
Common Shares [Member]
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common shares, vesting, stock based award | shares									2,000
Subsequent Event [Member]
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Cash dividends per share | $ / shares	$ 0.01
Dividends payable, date declared	Nov. 01, 2023
Wells Fargo Securities, LLC [Member] | At-The-Market Offerings [Member]
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Proceeds from issuance of common shares		$ 60,000
Core Laboratories Inc.
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock, par value per share | (per share)						$ 0.01			$ 0.01		€ 0.02
Amount decreased due to difference between the total par value of common shares									$ 700
Equity related Transaction costs									$ 4,600

Equity - Schedule of Accumulate

Equity - Schedule of Accumulated Other Comprehensive Income (Loss) Net of Income Taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss	$ (5,019)	$ (5,108)
Interest rate swaps - net gain (loss) on fair value	1,181	1,331
Total accumulated other comprehensive income	$ (3,838)	$ (3,777)

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Jun. 28, 2023	Sep. 30, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Total long-term debt		$ 181,000	$ 181,000		$ 175,000
Face amount		75,000	75,000
Net loss included in accumulated other comprehensive income	$ 400		500
Net loss included in AOCI expected to be reclassified into earnings	10,000
Gain on forward interest rate swap agreements terminated and settlements			1,200
Long-term debt, percentage bearing fixed interest, amount		110,000	110,000
Long-term debt, percentage bearing variable interest, amount		71,000	71,000
Credit Facility [Member]
Derivatives, Fair Value [Line Items]
Total long-term debt		71,000	71,000	$ 0	$ 40,000
Net loss reclassified to interest expense		200
2023 Senior Notes [Member]
Derivatives, Fair Value [Line Items]
Face amount	$ 50
Net loss included in accumulated other comprehensive income			1,700
Net loss included in AOCI expected to be reclassified into earnings			$ 1,300
Maximum [Member]
Derivatives, Fair Value [Line Items]
Basis spread on variable rate			3%
Maximum [Member] | Amended Credit Facility | SOFR [Member]
Derivatives, Fair Value [Line Items]
Basis spread on variable rate			3%
Maximum [Member] | 2023 Senior Notes [Member]
Derivatives, Fair Value [Line Items]
Derivative, fixed interest rate	7.50%
Minimum [Member]
Derivatives, Fair Value [Line Items]
Basis spread on variable rate			2%
Minimum [Member] | Amended Credit Facility | SOFR [Member]
Derivatives, Fair Value [Line Items]
Basis spread on variable rate			2%
Minimum [Member] | 2023 Senior Notes [Member]
Derivatives, Fair Value [Line Items]
Derivative, fixed interest rate	7.25%
Interest Rate Swap No. 1 [Member]
Derivatives, Fair Value [Line Items]
Derivative, notional amount		$ 25,000	$ 25,000
Derivative, fixed interest rate		2.50%	2.50%
Derivative, maturity date			Aug. 29, 2024
Interest Rate Swap No. 2 [Member]
Derivatives, Fair Value [Line Items]
Derivative, notional amount		$ 25,000	$ 25,000
Derivative, fixed interest rate		1.30%	1.30%
Derivative, maturity date			Feb. 28, 2025
Forward Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Derivative, notional amount		$ 60,000	$ 60,000
Derivative, term of contract			10 years
Forward Interest Rate Swap [Member] | Maximum [Member]
Derivatives, Fair Value [Line Items]
Long term debt terms		11 years	11 years

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Interest Rate Swap No. 1 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) on interest rate cash flow hedges	$ 0	$ 84	$ 211	$ 264
Interest Rate Swap No. 2 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) on interest rate cash flow hedges	(415)	165	(398)	498
Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) on interest rate cash flow hedges	$ (415)	$ 249	$ (187)	$ 762

Financial Instruments - Summary

Financial Instruments - Summary of Fair Value Balances (Details) - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Company owned life insurance policies	[1]	$ 23,635	$ 23,787
Deferred compensation plan, assets		23,635	23,787
Deferred compensation liabilities		16,912	16,284
Deferred compensation plan, liability		16,912	16,284
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Company owned life insurance policies	[1]	23,635	23,787
Deferred compensation plan, assets		23,635	23,787
Deferred compensation liabilities		16,912	16,284
Deferred compensation plan, liability		$ 16,912	$ 16,284
[1] (1) Company owned life insurance policies have cash surrender value and are intended to assist in funding deferred compensation liabilities and other benefit plans.

Other (Income) Expense, Net - S

Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Other Income Expense [Line Items]
Other (Income) expense, net	$ 673	$ (1,781)	$ (423)	$ (62)
(Gain) loss on sale of assets [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	(76)	(96)	(109)	(363)
Results of non-consolidated subsidiaries [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	(135)	(59)	(334)	(173)
Foreign exchange (gain) loss, net [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	238	(1,303)	(292)	(462)
Rents and royalties [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	(205)	(222)	(460)	(533)
Return on pension assets and other pension costs [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	(336)	(132)	(992)	(416)
Loss on lease abandonment and other exit costs [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	505	0	1,146	0
Assets write-down [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	128	0	1,143	0
Severance and other charges [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	0	0	0	3,332
Insurance and other settlement [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	0	0	(604)	(669)
ATM termination costs [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	455	0	455	0
Other, net [Member]
Other Income Expense [Line Items]
Other (Income) expense, net	$ 99	$ 31	$ (376)	$ (778)

Other (Income) Expense, Net - A

Other (Income) Expense, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Partial Proceeds From insurance Settlement Investing Activities			$ 0.7
Real Estate Inventory, Capitalized Interest Costs Incurred	$ 0.5	$ 1.1
Right of use assets write down	0.1	1.1
Expropriation settlement from related party		0.6
ATM Program [Member]
Written off previously deferred cost	$ 0.5	$ 0.5

Other (Income) Expense, Net - F

Other (Income) Expense, Net - Foreign Currency (Gain) Loss, Net By Currency (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	$ 238	$ (1,303)	$ (292)	$ (462)
British Pound [Member]
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	(30)	(187)	(211)	(195)
Canadian Dollar [Member]
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	98	130	92	159
Colombian Peso [Member]
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	(12)	(309)	120	(398)
Euro [Member]
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	13	(501)	(4)	(956)
Russian Ruble [Member]
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	15	(533)	(326)	572
Turkish Lira [Member]
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	(24)	(7)	(472)	117
Other Currencies, Net [Member]
Other Income Expense [Line Items]
Foreign exchange (gain) loss, net	$ 178	$ 104	$ 509	$ 239

Income Tax Expense - Additional

Income Tax Expense - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	20%	33.50%	14.40%	25.50%
Unrepatriated earnings of our Russian subsidiary				$ 12,000
Accrued withholding taxes			$ 600
Income tax expense (benefit)	$ 2,305	$ 3,856	$ (4,344)	$ 4,449

Earnings per Share - Schedule o

Earnings per Share - Schedule of Weighted Average Number of Shares (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Weighted average common shares outstanding - basic	46,692	46,338	46,667	46,319
Restricted shares	106	62	96	107
Performance shares	806	612	773	691
Weighted average common shares outstanding - diluted	47,604	47,012	47,536	47,117

Segment Reporting - Schedule of

Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | Segment			2
Revenue	$ 125,343	$ 125,966	$ 381,580	$ 362,164
Segment operating income (loss)	14,672	14,645	40,059	25,906
Total assets (at end of period)	592,414	570,190	592,414	570,190	$ 578,354
Capital expenditures	3,461	2,702	7,843	8,195
Depreciation and amortization	3,929	4,171	11,910	13,088
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue	0	0	0	0
Reservoir Description [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	85,145	78,996	248,717	229,567
Segment operating income (loss)	12,992	9,798	28,780	16,085
Total assets (at end of period)	302,769	303,102	302,769	303,102
Capital expenditures	2,840	1,590	5,879	5,721
Depreciation and amortization	2,712	2,872	8,374	8,804
Reservoir Description [Member] | Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue	16	103	145	424
Production Enhancement [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	40,198	46,970	132,863	132,597
Segment operating income (loss)	1,544	4,417	10,324	8,447
Total assets (at end of period)	163,395	150,005	163,395	150,005
Capital expenditures	237	1,096	1,237	1,984
Depreciation and amortization	1,049	1,075	3,034	3,581
Production Enhancement [Member] | Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue	25	89	144	183
Corporate and Other [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	0	0	0	0
Segment operating income (loss)	136	430	955	1,374
Total assets (at end of period)	126,250	117,083	126,250	117,083
Capital expenditures	384	16	727	490
Depreciation and amortization	168	224	502	703
Corporate and Other [Member] | Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue	$ (41)	$ (192)	$ (289)	$ (607)